FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Fulgent Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$20.10+0.29 (+1.46%)
Close on Oct 19, 2026
- Market cap
- $562.90M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.58 (−11.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Fulgent Genetics, Inc. grew revenue 6.8% to $323.93M over the twelve months to Jun 30, 2026. Free cash flow was -$103.79M.
Revenue
$323.93M
+6.8% vs. a year earlier
Operating income
-$122.28M
TTM Q2 2026
Free cash flow
-$103.79M
TTM Q2 2026
EPS, diluted
-$2.82
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $562.90M
- P/E ratio
- –
- Price to sales
- 1.74
- Price to book
- 0.56
- Dividend yield
- –
- Free cash flow yield
- -18.44%
Fundamentals
- Revenue
- $323.93M
- Net income
- -$84.38M
- EPS, diluted
- -$2.82
- Free cash flow
- -$103.79M
- Book value per share
- $35.77
- Diluted shares
- 28M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$323.93M+6.8% YoY
Gross profit
$115.26M-5.1% YoY
Operating income
-$122.28M
Net income
-$84.38M
EPS, diluted
-$2.82
Free cash flow
-$103.79M
Reported periodTrailing twelve months